Abstract:To retrospectively analyze the effect of postoperative intensity-modulated radiation therapy (IMRT) on the recurrence and survival in patients with lymph node positive or Stage III thoracic esophageal squamous cell carcinoma (TESCC), and evaluate the role of postoperative IMRT in the TESCC therapy. From January 2004 to June 2009, 535 patients with TESCC underwent radical resection with or without postoperative IMRT were eligible for analysis. Inclusion criteria: (1) having undergone radical resection (R0); (2) a diagnosis of squamous cell carcinoma confirmed by pathological studies; (3) Karnofsky performance status scale ≥70; (4) Preoperative neoadjuvant therapy was not proceeded; (5) postoperative pathologic stage was IIb or III. According to UICC02 stage classification, 122 patients were stage IIb and 413 patients were stage III. Patients were grouped to surgery alone (n = 345) and surgery plus postoperative IMRT (n = 190). The median total dose in postoperative IMRT was 60 Gy. The Kaplan-Meier method was used to calculate the survival rates, and the log-rank test was used for univariate analysis. The chi-square test was used to analyze the sites of failure of esophageal cancer with different treatments. The 1-, 3-, and 5-year overall survival (OS) and disease-free survival (DFS) for all the patients were 79.5%, 42.7%, 32.8%, and 67.2%, 38.0%, 32.5%, and the median OS and DFS were 28.6 months and 21.5 months, respectively. For patients with stage IIb and stage III, the 5-year OS rates were 45.3% and 29.2%, respectively (p = 0.001). The 5-year OS in the patients with lymph node positivity was 28.5% in the group receiving surgery alone and 38.9% in the group undergoing surgery plus postoperative IMRT (p = 0.000). The 5-year OS rates in patients with stage III was 24.3% in the surgery group and 38.0% in the surgery plus postoperative IMRT group, respectively (p = 0.001). Use of postoperative IMRT resulted in significant decrease in intrathoracic recurrence from 33.6% to 13.3% (p = 0.000) as well as supraclavicular recurrence from 13.4% to 6.1% (p = 0.012), Similarly, use of postoperative IMRT obviously delayed the median local recurrence from 10.7 months to 20.7 months and the median system metastases from 8.8 months to 14.5 months. While systemic metastases increased from 21.6% to 30.4% (p = 0.032) by postoperative IMRT treatment. Postoperative IMRT reduced local recurrence and improved survival for patients with lymph node positive or stage III TESCC, which would provide rationale in establishing patient selection criteria for the postoperative IMRT for TESCC after surgery.

Comparison of Two Major Staging Systems in Predicting Survival and Recommendation of Postoperative Radiotherapy Based on the 11th Japanese Classification for Esophageal Carcinoma After Curative Resection: A Propensity Score-Matched Analysis

Prognostic Analysis and Comparison of the 2014 and 2018 International Federation of Gynecology and Obstetrics Staging System on Overall Survival in Patients with Stage IIB-IVA Cervix Carcinoma

Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma

Prognosis of esophageal squamous cell carcinoma patients with preoperative radiotherapy: Comparison of different cancer staging systems

Validation of the Postneoadjuvant Therapy Pathological Stage of the American Joint Committee on Cancer (AJCC) 8th Edition for Predicting Outcomes of Esophageal Squamous Cell Carcinoma (ESCC) Patients Receiving Neoadjuvant Chemoradiotherapy (CRT) Followed by Esophagectomy.

A New Clinical Staging System for Esophageal Cancer to Predict Survival after Definitive Chemoradiation or Radiotherapy

Applying post-neoadjuvant pathologic stage as prognostic tool in esophageal squamous cell carcinoma

Which Staging System Better Predicts 10-Year Survival for Gastric Cancer? A Study Using an International Multicenter Database

Validation of the American Joint Committee on Cancer (AJCC) 8th edition stage system for gastric cancer patients: a population-based analysis

Comparison of the TNM9th and 8th editions for localized and locally advanced anal squamous cell carcinoma treated nonsurgically and proposal of a new stage grouping system

Prognostic prediction and comparison of three staging programs for patients with advanced (T2-T4) esophageal squamous carcinoma after radical resection

Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinoma

Propensity score analysis comparing survival between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma

Postoperative Intensity Modulated Radiation Therapy Improved Survival of Lymph Node-Positive or Stage III Squamous Cell Carcinoma Esophagus

Comparative Effectiveness of the Revised American Joint Committee on Cancer Staging System

Clinical study of non-operative staging of esophageal squamous cell carcinoma underwent intensity-modulated radiotherapy combined with chemotherapy

Proposed Modification of the 8th Edition of the AJCC Staging System for Gastric Cancer

Comparison of the Prognostic Difference Between Yptnm and Equivalent Ptnm Stages in Esophageal Squamous Cell Carcinoma Based on the 8th Edition of AJCC Classification

Evaluation of the Eighth Edition of the American Joint Committee on Cancer TNM Staging System for Gastric Cancer: an Analysis of 7371 Patients in the SEER Database

Is the new distribution of early esophageal adenocarcinoma stages improving the prognostic prediction of the 8 edition of the TNM staging system for esophageal cancer?

Evaluating the eighth edition TNM staging system for esophageal cancer among patients receiving neoadjuvant therapy: A SEER study